MD FLT3-ITD Follow up Mutation MRD Analysis

The treatment of acute myeloid leukemia (AML) has become a model for precision medicine. The FLT3 ITD minimal residual disease (MRD) test is a next-generation sequencing (NGS)-based, targeted deep-sequencing assay designed to detect internal tandem duplications (ITDs) in the FLT3 gene, ranging from 3 base pairs to over 200 base pairs in size. Once a specific ITD has been identified in an initial sample, it can be accurately monitored in subsequent samples with a sensitivity of 0.005%. This capability allows for the detection of the persistent FLT3 ITD mutation even in patients who show no visible signs of disease, helping clinicians determine whether to continue or adjust treatment. MRD detection via NGS has proven valuable in predicting clinical outcomes and providing actionable results, facilitating early intervention, confirming disease status before transplant, and bolstering confidence in remission status.

Next-generation sequencing of PCR products is employed to identify DNA sequences corresponding to previously detected mutations identified at diagnosis.

Clinical specimens were reviewed for following FLT3 ITD transcripts.

10 days

• 10 ml peripheral blood (PB) in purple-top (lavender top) tube (EDTA Vacutainer), sent on wet ice
  or
  
• 2–5 ml of bone marrow aspirate (BM), sent on wet ice

81245

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.